Hims Stock Reacts to FDA Review of Peptides
Hims (HIMS) stock rose following the FDA's announcement of a July review on expanding peptide compounding access, which aligns with the company's strategic shift toward peptides in its weight-loss and core businesses. The FDA's decision has been viewed as a potential long-term growth catalyst for Hims, supported by strong financials and recent acquisitions.
Tickers: $HIMS
Topics: FDA Hims peptides regulatory developments stock price movement